Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Liu Z, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. Lancet Gastroenterol Hepatol. 2023. PMID: 36481043 Free PMC article.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Lin S, et al. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. Nat Commun. 2022. PMID: 35296643 Free PMC article.
Seams.
Masters F. Masters F. Nature. 2021 Oct 6. doi: 10.1038/d41586-021-02698-x. Online ahead of print. Nature. 2021. PMID: 34616087 No abstract available.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421
Molecular phylogeny of the Pectinoidea (Bivalvia) indicates Propeamussiidae to be a non-monophyletic family with one clade sister to the scallops (Pectinidae).
Smedley GD, Audino JA, Grula C, Porath-Krause A, Pairett AN, Alejandrino A, Lacey L, Masters F, Duncan PF, Strong EE, Serb JM. Smedley GD, et al. Among authors: masters f. Mol Phylogenet Evol. 2019 Aug;137:293-299. doi: 10.1016/j.ympev.2019.05.006. Epub 2019 May 14. Mol Phylogenet Evol. 2019. PMID: 31100513
Prior storm experience moderates water surge perception and risk.
Webster GD, Agdas D, Masters FJ, Cook CL, Gesselman AN. Webster GD, et al. Among authors: masters fj. PLoS One. 2013 May 30;8(5):e62477. doi: 10.1371/journal.pone.0062477. Print 2013. PLoS One. 2013. PMID: 23737941 Free PMC article.
Wind speed perception and risk.
Agdas D, Webster GD, Masters FJ. Agdas D, et al. Among authors: masters fj. PLoS One. 2012;7(11):e49944. doi: 10.1371/journal.pone.0049944. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226230 Free PMC article.
88 results